JPMorgan Chase & Co. Buys 65,972 Shares of Evolus, Inc. (NASDAQ:EOLS)

JPMorgan Chase & Co. boosted its stake in Evolus, Inc. (NASDAQ:EOLS) by 63.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 169,926 shares of the company’s stock after purchasing an additional 65,972 shares during the quarter. JPMorgan Chase & Co. owned about 0.27% of Evolus worth $2,753,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Quarry LP acquired a new position in shares of Evolus during the 2nd quarter worth about $54,000. Profund Advisors LLC bought a new stake in Evolus in the second quarter valued at approximately $130,000. Point72 Asset Management L.P. acquired a new stake in Evolus in the third quarter worth $132,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Evolus during the third quarter worth $191,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Evolus by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock valued at $197,000 after buying an additional 4,780 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Thursday, November 7th.

Evolus Stock Performance

Shares of EOLS opened at $10.51 on Tuesday. The firm has a market cap of $665.49 million, a P/E ratio of -11.55 and a beta of 1.32. Evolus, Inc. has a twelve month low of $9.25 and a twelve month high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm’s 50 day moving average price is $11.65 and its two-hundred day moving average price is $13.73.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.